- Home
- HHS vs RFL Comparison
HHS vs RFL Comparison
Compare HHS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- RFL
- Stock Information
- Founded
- HHS 1923
- RFL 2017
- Country
- HHS United States
- RFL United States
- Employees
- HHS N/A
- RFL N/A
- Industry
- HHS Advertising
- RFL Real Estate
- Sector
- HHS Consumer Discretionary
- RFL Finance
- Exchange
- HHS Nasdaq
- RFL Nasdaq
- Market Cap
- HHS 55.0M
- RFL 48.4M
- IPO Year
- HHS N/A
- RFL N/A
- Fundamental
- Price
- HHS $6.90
- RFL $2.00
- Analyst Decision
- HHS
- RFL
- Analyst Count
- HHS 0
- RFL 0
- Target Price
- HHS N/A
- RFL N/A
- AVG Volume (30 Days)
- HHS 14.5K
- RFL 47.2K
- Earning Date
- HHS 11-07-2024
- RFL 10-28-2024
- Dividend Yield
- HHS N/A
- RFL N/A
- EPS Growth
- HHS N/A
- RFL N/A
- EPS
- HHS N/A
- RFL N/A
- Revenue
- HHS $187,093,000.00
- RFL $540,000.00
- Revenue This Year
- HHS N/A
- RFL N/A
- Revenue Next Year
- HHS $4.05
- RFL N/A
- P/E Ratio
- HHS N/A
- RFL N/A
- Revenue Growth
- HHS N/A
- RFL 92.86
- 52 Week Low
- HHS $5.39
- RFL $1.29
- 52 Week High
- HHS $8.87
- RFL $2.14
- Technical
- Relative Strength Index (RSI)
- HHS 30.23
- RFL 74.68
- Support Level
- HHS $7.09
- RFL $1.65
- Resistance Level
- HHS $7.46
- RFL $1.94
- Average True Range (ATR)
- HHS 0.23
- RFL 0.10
- MACD
- HHS -0.04
- RFL 0.02
- Stochastic Oscillator
- HHS 20.39
- RFL 100.00
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.